Results 91 to 100 of about 1,588,451 (244)

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

open access: yesAdvanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee   +6 more
wiley   +1 more source

An Activity‐Reinforced P‐Modified Single‐Atom Cu Nanozyme Potentiates IDO Blockade‐Induced Tumor Radiotherapy

open access: yesAdvanced Science, EarlyView.
A phosphorus‐modified single‐atom copper nanozyme delivering the IDO1 inhibitor 1‐methyl‐tryptophan enhances breast cancer radioimmunotherapy by simultaneously relieving hypoxia and inducing immunogenic cell death through dual enzyme activities while blocking tryptophan metabolism to suppress regulatory T cell function.
Wei Zhao   +11 more
wiley   +1 more source

High‐Throughput Screening and Interpretable Machine Learning for Rational Design of Bimetallic Catalysts for Methane Activation

open access: yesAdvanced Science, EarlyView.
ABSTRACT Methane's efficient catalytic removal is vital for sustainable development. Bimetallic catalysts, though promising for methane activation, pose a design challenge due to their complex compositional space. This work introduces an integrated framework that combines high‐throughput density functional theory (DFT) and interpretable machine ...
Mingzhang Pan   +8 more
wiley   +1 more source

The Prognostic and Therapeutic Value of PD-L1 in Glioma

open access: yesFrontiers in Pharmacology, 2019
Glioma is the most common type of primary brain tumors. After standard treatment regimen (surgical section, radiotherapy and chemotherapy), the average survival time remains merely around 14 months for glioblastoma (grade IV glioma).
Ruo Qiao Chen   +6 more
doaj   +1 more source

PD-L1+ virions can be produced from PD-L1+ CD4 T cells or monocyte-derived macrophages in vitro.

open access: yes, 2022
Activated CD4 T cells or MDM from HIV-uninfected individuals (N = 7) were exposed or not to HIV lab-derived variants in presence or in absence of emtricitabin.
Riddhima Banga (634344)   +11 more
core   +1 more source

Blood Cell‐Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING‐Amplified Photothermal Immunity for Metastatic Triple‐Negative Breast Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Whole‐blood biomimetic engineering transforms liquid metal nanoparticles into a tripartite immunotherapeutic platform that orchestrates regulatory T‐cell depletion, photothermal‐induced immunogenic cell death, and activation of the stimulator of interferon genes pathway.
Nina Sang, Eijiro Miyako
wiley   +1 more source

Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy

open access: yesActa Pharmaceutica Sinica B
Immune checkpoint blockade (ICB) therapy targeting PD-L1 via monoclonal antibody (mAb) has shown extensive clinical benefits in the diverse types of advanced malignancies. However, most patients are completely refractory to ICB therapy owing to the PD-L1
Youngjoo Lee   +9 more
doaj   +1 more source

PD-L1 Status in Refractory Lymphomas - Fig 2

open access: yes, 2016
(A): Hematoxylin and Eosin (H&E) slide of a case of lymphocyte depleted variant of classical Hodgkin lymphoma (cHL); (B): The tumor cells were diffusely (100%) and strongly (3+) positive for PD-L1 protein by immunohistochemistry (clone: SP142); (C-D ...
Jeffery Kimbrough (3353009)   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy